Tag: NOXALK

Patentee Rights During Pendency Of Post-Grant Opposition

Issues: In the case of Novartis AG & ANR v Natco Pharma Ltd, Swiss Pharma major Novartis has been granted patent for novel and inventive compound “Certinib” for treatment of non-small cell lung cancer. The suit patent was filed claiming priority since 2007, and was granted on 28th September, 2015. Novartis came across NOXALK (Natco … Continue reading Patentee Rights During Pendency Of Post-Grant Opposition

Read more »